Vigilant Biosciences Closes $2 Million Oversubscribed Series A Financing
3/25/2014 10:04:47 AM
MIAMI--(BUSINESS WIRE)--Vigilant Biosciences, Inc. (“Vigilant”), developer of the “rinse and spit” test for assessing early risk of oral cancer, today announced the successful completion of a $2.0 million, oversubscribed Series A financing. The company received $2.3 million in total proceeds, including a $300,000 loan from the Florida Institute for the Commercialization of Public Research Seed Capital Acceleration Program.
Help employers find you! Check out all the jobs and post your resume.
comments powered by